FitLife Brands 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- FitLife Brands reported Q3 2026 revenue of $25.6 million, up 9% from Q3 2025, with growth from a full quarter of Erwin partially offset by a year-over-year decline in legacy FitLife.
- Online revenue was $11.8 million, up 15% year over year and 46% of total revenue; gross margin was 37.7%, compared with 37.2% a year ago and 37.0% in Q2 2026.
- Contribution, defined as gross profit less advertising and marketing expense, grew 10% to $8.1 million, or 31.5% of revenue.
- Net income was $1.6 million, up 71% from $0.9 million a year ago; diluted earnings per share was $0.16 versus $0.09, and basic earnings per share was $0.17 versus $0.10.
- Adjusted EBITDA was $3.3 million, compared with $3.8 million a year ago; trailing 12-month revenue was $103.4 million and adjusted EBITDA was $13.7 million.
- Legacy FitLife revenue was $12.6 million, up 1.5% sequentially; wholesale revenue was down 34% year over year, primarily due to reduced sales to certain retail partners, mainly GNC.
- Legacy FitLife online revenue was $8.2 million, or 65% of its revenue; gross margin was 41.6%, versus 39.3% a year ago, and contribution was $4.2 million, or 33.6% of revenue.
- Erwin generated $13.0 million of revenue, up 91% from the partial period a year ago; online revenue rose 5% sequentially to $3.6 million and represented 28% of Erwin revenue.
- Erwin's annual revenue run rate on Amazon exceeded $12 million at the end of Q3; gross margin was 34.0% and contribution was $3.9 million, or 29.6% of revenue.
- The company ended the quarter with $39.3 million of debt, including $34.5 million on its term loan and $4.8 million on its revolving line of credit; net debt rose from $37.0 million at Q2-end to $38.6 million at Q3-end.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Please note, this conference is being recorded. I will now turn the conference over to your host, Dayton Judd.
You may begin. Good afternoon.
I'd like to welcome everyone to FitLife's Q3 2026 earnings call. We appreciate you taking the time to join us this afternoon. Joining me on the call is FitLife's President, Ryan Hansen, and FitLife's CFO, Jakob York. For the Q3 2026, total revenue was $25.6 million, an increase of 9% from the Q3 2025. Growth came from a full quarter of Irwin, partially offset by a year-over-year revenue decline for Legacy FitLife. Online revenue was $11.8 million, an increase of 15% year-over-year, and represented 46% of total revenue. Gross margin was 37.7%, up from 37.2% a year ago. Excluding the $0.4 million of inventory step-up amortization in the prior year quarter, the gross margin during the Q3 last year was 38.9%. Gross margin improved sequentially from 37.0% in the second quarter.
Contribution, which we define as gross profit less advertising and marketing expense, grew 10% to $8.1 million, or 31.5% of revenue. Net income was $1.6 million, up 71% from $0.9 million a year ago. Diluted earnings per share was $0.16 compared to $0.09 last year, and basic earnings per share was $0.17 compared to $0.10 last year. Adjusted EBITDA was $3.3 million compared to $3.8 million a year ago. For the trailing 12 months, the company generated $103.4 million of revenue and $13.7 million of adjusted EBITDA. Although some brands and channels continue to be challenged, others are growing. Sequentially, for each of the past four quarters, revenue for the combined business has been relatively stable between $25.3 million and $26.5 million, and adjusted EBITDA has also been consistently between $3.3 million and $3.7 million.
During the Q3, we completed a restructuring initiative to improve efficiency and lower our cost structure. We recorded $0.3 million of restructuring expense, primarily severance, and we expect the initiative to reduce annual OpEx by approximately $1.2 million, with savings beginning in the Q4 2026. Turning to brand-level performance, I'll start with Legacy FitLife, which includes MRC and MusclePharm. Legacy FitLife revenue was $12.6 million, and it has been stable throughout the year, growing 1.5% sequentially in the Q3 2026 compared to the Q2 2026. Year-over-year, wholesale revenue for Legacy FitLife was down 34%, primarily due to reduced sales to certain retail partners, mainly GNC. However, wholesale revenue for Legacy FitLife has increased sequentially from Q1 to Q2 and from Q2 to Q3, largely offsetting the declines in online revenue driven by MRC.
Online revenue for Legacy FitLife was $8.2 million, or 65% of total revenue. Gross margin for Legacy FitLife was 41.6%, up from 39.3% a year ago, and similar to the second quarter's 41.7% gross margin. Contribution from Legacy FitLife was $4.2 million, or 33.6% of revenue, up from 31.5% during the third quarter of 2025. Sequentially, the Legacy FitLife business has been remarkably stable over the last three quarters. Total revenue has ranged between $12.4 million and $12.6 million, with sequential growth in wholesale revenue largely offsetting the sequential declines in online revenue driven by MRC. Gross margin has ranged between 41.2% and 41.7%, and contribution has ranged between $4.2 million and $4.3 million. The MusclePharm brand is doing well, with online revenue during the quarter reaching an all-time high and wholesale revenue reaching its second-highest quarter since we have owned the brand, all of this at significantly higher gross margin.
Moving on now to Irwin. Irwin generated $13.0 million of revenue, a 91% increase from the partial period last year. Online revenue rose 5% sequentially to $3.6 million and now represents 28% of Irwin's revenue, up from approximately 5% a year ago. Irwin's annual revenue run rate on Amazon exceeded $12 million at the end of the third quarter. Wholesale revenue for Irwin during the quarter was $9.4 million. Gross margin for Irwin during the quarter was 34.0%, and contribution was $3.9 million, or 29.6% of revenue. Now, I'll provide a few additional high-level comments, and then we can open the call for questions. I know some of you like to track subscriber counts, so as of today, we have approximately 96,500 active Amazon subscribers, up from 94,000 when we held our previous earnings call in August.
Our business continues to be challenged by a weak consumer environment and some headwinds, such as Amazon algorithm changes and softness in the specialty retail and health food channels are outside our control. With that backdrop, though, we are building a stronger supply chain and new product pipeline, as well as a more efficient cost base. On a consolidated basis, online revenue continues to grow, with Irwin and MusclePharm delivering all-time highs during the quarter. We believe that the cost actions we have taken will favorably impact SG&A and cost of goods sold. These cost actions include the $1.2 million expected savings from the restructuring I previously mentioned, as well as additional non-headcount-related savings. We ended the quarter with $39.3 million of debt, consisting of $34.5 million on our term loan and $4.8 million on our revolving line of credit.
Our net debt increased slightly from $37.0 million at the end of the second quarter to $38.6 million at the end of the third quarter. Given our general trend of reducing indebtedness each quarter, I want to comment on the reasons for the increase. In short, working capital increased $3.5 million sequentially from $9.6 million at the end of the second quarter to $13.1 million at the end of the third quarter. More specifically, inventory increased $1.7 million, receivables increased $1.1 million, and prepaids increased $0.7 million, while payables only increased $0.3 million. A large part of the increase in working capital reflects deliberate decisions we made to lock in commodity pricing through forward purchases of whey protein and fish oil, two commodities facing sharp cost increases due to supply shortages.
With those payments made, we have locked in fixed-price fish oil for the majority of our needs over the next 12 months, and we expect working capital to normalize over time. Over time, we also expect these forward purchases will convert to cash at higher margins than if we had purchased on the spot market. Our weighted average cost of debt is approximately 6.7%, and we intend to continue deploying excess free cash flow toward debt reduction. That concludes my opening commentary, and we can now go ahead and open it up for questions.
Thank you. At this time, we will be conducting a question-and-answer session. If you would like to ask a question, please press star one on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press star two if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. One moment, please, while we poll for questions. Once again, please press star one if you have a question or a comment. The first question comes from Ryan Meyers with Lake Street.
Please proceed. Hey, guys. Luke Fingerson on for Ryan Meyers.
You expect $1.2 million of annual OpEx savings beginning Q4. Should we expect this $300,000 benefit immediately, or does that ramp over a couple quarters?
Hey, Luke. That will be the number for Q4. The actions were actually taken, I am not going to remember exactly when, but call it mid-August. It was not kind of done at the end of the quarter. We should see kind of the full impact of that. In terms of cash, there is a $0.3 million charge that hits during Q3 in terms of cash out the door. About a third of that was paid out before the end of the third quarter, with the remainder being paid in the fourth quarter. P&L-wise, the full impact, and cash-wise, you will see some of that trailing into the fourth quarter.
Got it. On MRC, it continues to drive most of the Legacy FitLife online weakness. Are you seeing any evidence that the rate of decline is moderating?
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
5 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
